Investor Relations
A Message from the President
Download the latest IR documents
HOME
>
Investor Relations
Japanese
Investor Relations
Japanese
A Message from the President
Download the latest IR documents
IR News
News Releases
Apr. 23, 2021
(PDF/125KB)
Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
Apr. 13, 2021
(PDF/81KB)
Products
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA (vibegron) 75 mg Tablets for Patients with Overactive Bladder
Apr. 09, 2021
(PDF/113KB)
CSR
Sumitomo Dainippon Pharma Receives the "Intellectual Property Achievement Awards" for the First Time
Mar. 31, 2021
(PDF/194KB)
R&D
The GHIT Fund Awards Grant for the Development of a New Malaria Pre-erythrocytic Vaccine
Mar. 30, 2021
(PDF/85KB)
Corporate
Sumitovant Completes the "Going Private" Transaction with Our Consolidated Subsidiary, Urovant
more
RSS
Apr. 23, 2021
(PDF/125KB)
Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
Apr. 13, 2021
(PDF/81KB)
Products
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA (vibegron) 75 mg Tablets for Patients with Overactive Bladder
Apr. 09, 2021
(PDF/113KB)
CSR
Sumitomo Dainippon Pharma Receives the "Intellectual Property Achievement Awards" for the First Time
Mar. 31, 2021
(PDF/194KB)
R&D
The GHIT Fund Awards Grant for the Development of a New Malaria Pre-erythrocytic Vaccine
Mar. 30, 2021
(PDF/85KB)
Corporate
Sumitovant Completes the "Going Private" Transaction with Our Consolidated Subsidiary, Urovant
more
RSS
IR Calendar
May 12, 2021
FY2020 financial results announcement (1:00pm JST)(Planned)
May 13, 2021
Analysts meeting of financial results for FY2020
more
Managerial Policy
Business Units
Board Members and Executive Officers
Corporate Governance
Business Risks
IR Library
Financial Results Summary
Presentation
Integrated Report
Fact Book
Financial Data
Financial Highlights (Consolidated)
Fact Sheet
Stock Prices Chart
more
Stock & Ratings Information
Shareholders
Shareholders' Meeting
Analyst Coverage
Bonds & Ratings
Recommended Information Rankings
Presentation
Financial Results Summary
Integrated Report
Fact Book
IR Contact
FAQ
Disclaimer Regarding Forward-Looking Statements
Stance on Information Disclosure
IR Site Map
Related contents
About Us
R&D
CSR